Tag results:
p53
Pulmonary Cell News
ΔNp63 Regulates a Common Landscape of Enhancer Associated Genes in Non-Small Cell Lung Cancer
[Nature Communications] By utilizing a ΔNp63-specific conditional knockout mouse model and xenograft models of lung adenocarcinoma and squamous cell carcinoma, scientists found that ∆Np63 promoted NSCLC by maintaining the lung stem cells necessary for lung cancer cell initiation and progression in quiescence.
Prostate Cell News
Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer
[Molecular Cancer therapeutics] Investigators characterized responses to olaparib in sensitive LNCaP and C4-2B cells and developed two olaparib resistant derivative cell line models from each. In LNCaP and C4-2B cells, they found that olaparib induced massive DNA damage, leading to activation of the G2/M checkpoint, activation of p53, and cell cycle arrest.
Hepatic Cell News
Melatonin Is a Potential Oncostatic Agent to Inhibit HepG2 Cell Proliferation through Multiple Pathways
[Heliyon] Researchers investigated melatonin's antitumor molecular mechanisms to inhibit the proliferation of HepG2 cells.
Hepatic Cell News
Fasting Improves Therapeutic Response in Hepatocellular Carcinoma through p53-Dependent Metabolic Synergism
[Science Advances] Scientists showed in hepatocellular carcinoma (HCC) cells, xenografts, and patient-derived organoids that fasting improved sorafenib efficacy and acted synergistically to sensitize sorafenib-resistant HCC.
Intestinal Cell News
Combined MEK/MDM2 Inhibition Demonstrates Antitumor Efficacy in TP53 Wild-Type Thyroid and Colorectal Cancers with MAPK Alterations
[Scientific Reports] Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.
Pulmonary Cell News
RBL2/DREAM-Mediated Repression of the Aurora Kinase A/B Pathway Determines Therapy Responsiveness and Outcome in p53 WT NSCLC
[Scientific Reports] Researchers found heightened expression of RB-family (RBL) 2 and reduced expression of AURKA/B pathway genes was associated with improved outcomes in p53 wild-type but not p53 mutant NSCLC patients.